Medical & Clinical Emerging Markets, GSK, Istanbul, Turkey.
Medical Vaccines, GSK, Jeddah, Saudi Arabia.
Hum Vaccin Immunother. 2021 Oct 3;17(10):3710-3728. doi: 10.1080/21645515.2021.1920871. Epub 2021 Jul 2.
In most countries of the Middle East and Northern African (MENA) region, a high hepatitis A virus (HAV) endemicity has been documented. Few others, such as Saudi Arabia and Turkey, are transitioning from high to intermediate endemicity. There is a paucity of recently published HAV disease burden that could be useful to inform or strengthen relevant national hepatitis A vaccination policy and other prevention strategies in the region. This review summarizes information on HAV epidemiology before and after the implementation of a childhood hepatitis A vaccination program in Saudi Arabia and Turkey. In both countries, a clear shift in the age of first HAV exposure has been documented, with more homogeneous trends across regions in Saudi Arabia compared to Turkey. Utilizing the experience of Saudi Arabia and Turkey with hepatitis A vaccination, countries in the region are encouraged to foster discussions on potential vaccination strategies suitable for their own setting.
在中东和北非(MENA)地区的大多数国家,都有记录表明甲型肝炎病毒(HAV)高度流行。少数其他国家,如沙特阿拉伯和土耳其,正从高度流行向中度流行过渡。最近发表的关于 HAV 疾病负担的资料很少,这些资料可能有助于为该地区提供信息或加强相关的国家甲型肝炎疫苗接种政策和其他预防策略。这篇综述总结了在沙特阿拉伯和土耳其实施儿童甲型肝炎疫苗接种计划前后 HAV 流行病学的信息。在这两个国家,都有记录表明首次 HAV 暴露的年龄发生了明显变化,与土耳其相比,沙特阿拉伯各地区的趋势更加一致。利用沙特阿拉伯和土耳其在甲型肝炎疫苗接种方面的经验,鼓励该地区各国就适合其自身情况的潜在疫苗接种策略进行讨论。